Buffalo, NY, June 2, 2016 - Empire Genomics, LLC (www.empiregenomics.com), a global molecular diagnostics firm specializing in oncology products and clinical services, announces the appointment of HemaTone Beijing Corporation as its authorized distributor in China. HemaTone Beijing provides products and services as a contract research organization (“CRO”), and to the in vitro diagnostic (“IVD”), medical devices markets in Beijing, China. This global alliance between Empire Genomics and HemaTone Beijing was driven by growing demand in the region, and is expected to generate in excess of $5 million of revenue for Empire Genomics over the 5 year term of the agreement.
Anthony Johnson, Empire Genomics’ Chief Executive Officer and President, asserts, “Finding a like-minded and experienced diagnostic partner such as HemaTone is crucial to our successful commercialization efforts in China. Additional key requirements for us include deep Chinese regulatory knowledge and customer penetration. We chose HemaTone as our partner based on their strong track record of success with both of these attributes. We are excited to begin working with the HemaTone organization to bring the best in personalized medicine to the Chinese marketplace.”
In 2015, within China’s population of 1.37 billion people, over 4 million new cancer cases were diagnosed. Furthermore, nearly 3 million cancer deaths were recorded during the same period. Lung cancer is the most common form, representing the leading cause of cancer deaths in China.
“Cancer is the primary cause of death in China. Accordingly, gene testing and advanced diagnostic technologies are very important in our market place. As I learned about Empire’s innovative operations and business model, I knew I wanted to do business with them,” stated Fujun Yu, HemaTone Beijing’s General Manager.
Distributors provide a detailed knowledge of local dynamics, as well as support logistics and deliver a high level of customer service through product education. Empire’s primary objective in building distributor relationships is to provide services to a broader range of international clients. This new relationship will facilitate the distribution of Empire’s personalized diagnostic testing products in China, as HemaTone Beijing provides product training and marketing support to its clients.
About Empire Genomics, LLC
Empire Genomics was created in 2006 from research started at the prestigious Roswell Park Cancer Institute in Buffalo, NY. It is a molecular diagnostics company that develops and offers a comprehensive menu of assay services for use in diagnosing and guiding precise therapeutic treatments for patients. The Company is committed to working with the scientific community to bring the best in genomic technologies to bear on the complex systems that biology questions. More information can be found at http://www.empiregenomics.com/.
Anthony Johnson, Empire Genomics’ Chief Executive Officer and President, asserts, “Finding a like-minded and experienced diagnostic partner such as HemaTone is crucial to our successful commercialization efforts in China. Additional key requirements for us include deep Chinese regulatory knowledge and customer penetration. We chose HemaTone as our partner based on their strong track record of success with both of these attributes. We are excited to begin working with the HemaTone organization to bring the best in personalized medicine to the Chinese marketplace.”
In 2015, within China’s population of 1.37 billion people, over 4 million new cancer cases were diagnosed. Furthermore, nearly 3 million cancer deaths were recorded during the same period. Lung cancer is the most common form, representing the leading cause of cancer deaths in China.
“Cancer is the primary cause of death in China. Accordingly, gene testing and advanced diagnostic technologies are very important in our market place. As I learned about Empire’s innovative operations and business model, I knew I wanted to do business with them,” stated Fujun Yu, HemaTone Beijing’s General Manager.
Distributors provide a detailed knowledge of local dynamics, as well as support logistics and deliver a high level of customer service through product education. Empire’s primary objective in building distributor relationships is to provide services to a broader range of international clients. This new relationship will facilitate the distribution of Empire’s personalized diagnostic testing products in China, as HemaTone Beijing provides product training and marketing support to its clients.
About Empire Genomics, LLC
Empire Genomics was created in 2006 from research started at the prestigious Roswell Park Cancer Institute in Buffalo, NY. It is a molecular diagnostics company that develops and offers a comprehensive menu of assay services for use in diagnosing and guiding precise therapeutic treatments for patients. The Company is committed to working with the scientific community to bring the best in genomic technologies to bear on the complex systems that biology questions. More information can be found at http://www.empiregenomics.com/.
